Focused on developing anti-infectives for immunocompromised patients, AiCuris is not limited to one proprietary platform or technology, but always aims to identify novel approaches. Current in-licensing interests comprise novel anti-virals and anti-fungals in late preclinical to clinical development, aiming to increase the quality of life of patients with low immune defenses.
Out-licensing ΙΙ
A resistance-breaking anti-bacterial with novel target in lipid A biosynthesis